VX-765: Potent, Selective Caspase-1 Inhibitor for Pyroptosis and Inflammation Research

Executive Summary: VX-765 is a potent, orally available caspase-1 inhibitor that selectively suppresses IL-1β and IL-18 secretion in cell and animal models (Yuan et al., 2022). The compound is metabolized in vivo to VRT-043198, its active form, ensuring targeted inhibition of caspase-1 with minimal off-target cytokine effects (APExBIO). VX-765 enables precision interrogation of pyroptosis—a form of programmed cell death critical in inflammatory and infectious pathologies. It is widely used for dissecting the caspase signaling pathway in research on rheumatoid arthritis, HIV-associated inflammation, and other chronic inflammatory diseases. Selective inhibition by VX-765 has been benchmarked in endothelial, macrophage, and lymphoid tissue models, providing robust, reproducible results across multiple experimental systems.

Biological Rationale

Caspase-1, also known as interleukin-1 converting enzyme (ICE), is a cysteine protease required for the maturation and secretion of pro-inflammatory cytokines IL-1β and IL-18 (Yuan et al., 2022). Caspase-1 activation is a hallmark of the inflammasome pathway, leading to pyroptosis—a lytic, inflammatory form of programmed cell death. Pyroptosis occurs in macrophages and endothelial cells in response to intracellular pathogens and oxidative stress and is implicated in the development of atherosclerosis, rheumatoid arthritis, and infectious diseases. Dysregulated caspase-1 activity amplifies inflammation and tissue damage, making selective inhibition a critical strategy in inflammation research. Unlike broad-spectrum caspase inhibitors, VX-765 targets the ICE/caspase-1 sub-family with high selectivity, directly modulating the IL-1β signaling pathway without affecting apoptosis or unrelated cytokines (APExBIO).

Mechanism of Action of VX-765, Caspase-1 inhibitor, potent and selective

VX-765 is an orally absorbed prodrug. In vivo, it is rapidly converted to VRT-043198, its pharmacologically active metabolite (APExBIO). VRT-043198 binds to the active site of caspase-1, blocking proteolytic cleavage of pro-IL-1β and pro-IL-18. This action prevents secretion of mature IL-1β and IL-18, key drivers of inflammatory signaling and cell recruitment. The inhibition is highly selective: VX-765 does not significantly suppress other cytokines such as TNFα, IL-6, IL-8, or IL-α, nor does it interfere with apoptosis pathways (VX-765 and the Future of Inflammatory Pathway Modulation). By targeting the pyroptosis pathway, VX-765 enables researchers to dissect the role of caspase-1 in cell death, cytokine release, and disease progression. This selectivity underpins its value as a molecular tool in both in vitro and in vivo inflammation models.

Evidence & Benchmarks

• VX-765 (10 μM, 1 h pre-treatment) reduces H₂O₂-induced pyroptosis and IL-1β release in human umbilical vein endothelial cells (HUVECs) (Yuan et al., 2022).
• Oral administration of VX-765 significantly reduces inflammation and cytokine secretion in mouse models of rheumatoid arthritis and skin inflammation (APExBIO).
• VX-765 prevents CD4 T-cell pyroptotic death in HIV-infected lymphoid tissue cultures in a dose-dependent manner (Precision Caspase-1 Inhibition in Disease Modeling).
• In cell-based assays, VX-765 suppresses release of IL-1β and IL-18 but does not alter TNFα, IL-6, or IL-8 secretion, supporting its high selectivity (Decoding Selective Caspase-1 Inhibition).
• VX-765 is highly soluble in DMSO (≥313 mg/mL) and ethanol (≥50.5 mg/mL) but insoluble in water; best stored desiccated at -20°C (APExBIO).

Applications, Limits & Misconceptions

VX-765 is primarily used as a selective inhibitor for dissecting the caspase-1 signaling pathway in cell culture and animal models. Key applications include:

• Studying inflammasome activation, pyroptosis, and cytokine maturation in macrophages and endothelial cells.
• Modeling autoimmune and chronic inflammatory diseases such as rheumatoid arthritis and atherosclerosis.
• Investigating HIV-associated CD4 T-cell death and other infectious disease mechanisms (VX-765: Precision Caspase-1 Inhibition in Disease Modeling – this article extends the focus from general inflammation to translational disease models).
• Optimizing cell-based assays for pyroptosis and cytokine release measurement (Optimizing Pyroptosis and Inflammation Assays with VX-765 – the present piece provides updated storage and solubility parameters).

Common Pitfalls or Misconceptions

• VX-765 does not inhibit apoptosis or necroptosis pathways; its action is specific to caspase-1-mediated pyroptosis.
• It is insoluble in water; improper dissolution can lead to assay artifacts or inconsistent dosing.
• Long-term storage of reconstituted solutions is not recommended; activity may degrade—prepare fresh solutions for each experiment.
• VX-765 does not significantly affect TNFα, IL-6, or IL-8 secretion, so it is not a general anti-inflammatory agent.
• Due to its selectivity, VX-765 is not suitable for studies requiring broad-spectrum caspase inhibition.

Workflow Integration & Parameters

For cell-based assays, VX-765 is routinely used at 1–10 μM concentrations, with pre-treatment ranging from 30 minutes to 2 hours depending on cell type and stimulus (Yuan et al., 2022). For animal studies, oral administration protocols should be followed as per validated preclinical models. The compound’s high solubility in DMSO and ethanol ensures compatibility with most standard biochemical and cell culture workflows. Use substrates such as suc-YVAD-p-nitroanilide to monitor caspase-1 activity in enzymatic assays. Store VX-765 desiccated at -20°C; use freshly prepared solutions for optimal activity. For detailed product parameters and ordering, refer to the VX-765, Caspase-1 inhibitor, potent and selective product page (APExBIO).

Conclusion & Outlook

VX-765 (A8238, APExBIO) remains a reference standard for selective caspase-1 inhibition in inflammation and pyroptosis research. Its robust selectivity, oral bioavailability, and well-characterized activity profile make it invaluable for dissecting the role of the inflammasome pathway in disease. Ongoing studies continue to define its utility in new disease models and combinatorial strategies, further expanding its role in translational research. For expanded mechanistic and benchmarking details, see VX-765: Selective Caspase-1 Inhibitor for Inflammation Research – this article clarifies selectivity and solubility benchmarks for advanced users.